Cefpodoxime is a third-generation cephalosporin antibiotic, and Clavulanate is a beta-lactamase inhibitor. This combination is used to treat bacterial infections by both combating the bacteria and inhibiting bacterial enzymes (beta-lactamases) that could degrade cefpodoxime, enhancing its efficacy.
This combination of Cefpodoxime and Clavulanate is typically used for more resistant bacterial infections where beta-lactamase-producing bacteria are involved.
Upper Respiratory Tract Infections: Including sinusitis, pharyngitis, and tonsillitis.
Lower Respiratory Tract Infections: Such as bronchitis and pneumonia.
Urinary Tract Infections: Cystitis and pyelonephritis caused by beta-lactamase-producing pathogens.
Skin and Soft Tissue Infections: Infections such as cellulitis and wound infections caused by susceptible organisms.
Ear Infections: Otitis media, particularly in children, caused by beta-lactamase-producing organisms.
Other Infections: Infections caused by bacteria that produce beta-lactamase and are resistant to non-beta-lactamase-inhibitor cephalosporins.
The usual dose for adults is one tablet (200 mg/125 mg) taken every 12 hours for 5-10 days, depending on the severity and nature of the infection.
Dosage in children is usually determined by body weight. A typical dose for children may be calculated based on 10 mg/kg of Cefpodoxime divided into two doses, but the tablet form is typically not suitable for young children who may require liquid formulations.
This combination should be avoided in patients with a known allergy to cephalosporins or penicillins due to potential cross-reactivity.
Cefpodoxime is primarily excreted via the kidneys, so caution is required in patients with impaired renal function. Dosage adjustments may be necessary, and renal function should be monitored throughout treatment.
Caution is advised in patients with liver dysfunction, as Clavulanate can affect liver enzymes. Hepatic function should be monitored if therapy is prolonged.
Both Cefpodoxime and Clavulanate may cause gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain.
Broad-Spectrum Activity: Combines Cefpodoxime, a third-generation cephalosporin, with Clavulanate to treat a wide range of bacterial infections, including respiratory, urinary, and skin infections.
Enhanced Effectiveness: Clavulanate helps protect Cefpodoxime from being broken down by beta-lactamase enzymes produced by certain resistant bacteria.
Effective Against Resistant Bacteria: Provides treatment for beta-lactamase-producing bacteria that are resistant to many other antibiotics.
Convenient Tablet Form: Easy-to-administer tablet suitable for adults and children who can swallow tablets.
Well-Tolerated: Generally well-tolerated with mild side effects like diarrhea or nausea.